"Unlocking Opportunities: Kronox Lab Sciences IPO Analysis and Expert Insights"

Kronox Lab Sciences IPO: GMP, Review, Subscription Status, and More - Should You Apply?

Are you considering investing in the latest IPO? Kronox Lab Sciences Limited has just launched its Initial Public Offering (IPO), promising an exciting opportunity for investors. Let's delve into the details, from the Grey Market Premium (GMP) to subscription status and expert reviews, to help you make an informed decision.

Starting with the basics, Kronox Lab Sciences Limited's IPO opened today, offering a total worth of ₹130.15 crore. The bidding process will continue until June 5th, 2024. It's important to note that this IPO is an Offering for Sale (OFS), meaning it won't directly impact the company's balance sheet. The price band for the IPO is set between ₹129 to ₹136 per equity share.

Grey Market Premium (GMP): One of the key indicators in the IPO market is the Grey Market Premium (GMP). Currently, shares of Kronox Lab Sciences Limited are trading at a premium of ₹83 in the grey market, indicating strong demand.

Subscription Status: Within just half an hour of opening, the book build issue was fully subscribed. By 12:15 PM on the first day, the public issue was oversubscribed by 3.84 times. The retail portion saw a subscription of 5.59 times, while the NII segment reached 4.88 times subscription.

Important IPO Details:Price Band: ₹129 to ₹136 per equity share.
Date: Opened today, closing on June 5th, 2024.
Size: ₹130.15 crore through an OFS offering.
Lot Size: One lot comprises 110 company shares.
Allotment Date: Expected on Thursday, June 6th, 2024.
Registrar: KFin Technologies Limited.
Listing: Proposed for BSE and NSE.
Listing Date: Expected on Monday, June 10th, 2024.

Now, the crucial question arises: Should you apply for Kronox Lab Sciences IPO?

Review: According to Asit C Mehta, Kronox Lab Sciences Ltd. specializes in manufacturing and marketing High Purity Speciality Fine Chemicals, catering to various industries worldwide. The company boasts an in-house research, development, and testing laboratory (RDT Laboratory), indicating a commitment to innovation and quality.

Axis Capital highlights the company's impressive financial performance, with revenues growing at a CAGR of 23.70% between Fiscal 2021 to 2023, reaching ₹95.58 crore. Additionally, EBITDA grew at a CAGR of 21.90%, and the company maintains a zero-debt position, showcasing a robust balance sheet and healthy cash flow.

Expert Recommendations: Swastika Investmart has given a 'buy' tag to the IPO, suggesting confidence in its potential. However, SMC Global and JM Financial have not rated the book build issue, emphasizing the importance of individual research and analysis.

In conclusion, the Kronox Lab Sciences IPO presents a promising opportunity for investors. With strong demand evidenced by the GMP and oversubscription, coupled with positive expert reviews and the company's impressive financials, it may be a worthwhile investment. However, as with any investment decision, it's essential to conduct thorough research and consult certified experts before proceeding.

Remember, your investment decisions should align with your financial goals and risk tolerance. Happy investing!